Influence of osmolality on gastrointestinal fluid volume and drug absorption: potential impact on oral salt supplementation.

Drug absorption Gastrointestinal tract Membrane permeability Osmolality Pharmacokinetics

Journal

Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177

Informations de publication

Date de publication:
01 Sep 2021
Historique:
received: 02 04 2021
accepted: 10 06 2021
entrez: 1 9 2021
pubmed: 2 9 2021
medline: 2 9 2021
Statut: epublish

Résumé

The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is the most frequent cause of hyponatremia in patients with cerebrovascular disease, and is often treated with oral salt tablets. However, we have shown that osmolality-dependent variations in gastrointestinal (GI) fluid volume can alter the concentration of a poorly permeable drug in the GI tract, potentially affecting its absorption. Here, we examined the effect of ingestion of hyperosmotic solution (10% NaCl) on drug concentration and absorption in the GI tract. The effects of osmolality on luminal fluid volume and drug absorption in rat intestine (jejunum, ileum and colon) were examined by means of an in situ closed loop method using fluorescein isothiocyanate-dextran 4000 (FD-4) and atenolol. In vivo absorption in rats was determined by measuring the plasma concentration after oral administration of the test compounds dissolved in purified water or hyperosmotic solution (10% NaCl). Administration of hyperosmotic solution directly into the GI tract significantly increased the GI fluid volume, owing to secretion of water into the lumen. After administration in hyperosmotic solution, the luminal concentration of non-permeable FD-4 was significantly lower than the initial dosing concentration, whereas after administration in purified water, the luminal concentration exceeded the initial concentration. The fraction absorbed of atenolol was markedly lower after administration in hyperosmotic solution than after administration in purified water. An in vivo pharmacokinetic study in rats was consistent with these findings. Administration of hyperosmotic NaCl solution increased GI fluid volume and reduced the plasma level of orally administered atenolol. This may imply that oral salt tablets used to treat hyponatremia in SIADH patients could decrease the intestinal absorption of concomitantly administered drugs, resulting in lower plasma exposure.

Sections du résumé

BACKGROUND BACKGROUND
The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is the most frequent cause of hyponatremia in patients with cerebrovascular disease, and is often treated with oral salt tablets. However, we have shown that osmolality-dependent variations in gastrointestinal (GI) fluid volume can alter the concentration of a poorly permeable drug in the GI tract, potentially affecting its absorption. Here, we examined the effect of ingestion of hyperosmotic solution (10% NaCl) on drug concentration and absorption in the GI tract.
METHODS METHODS
The effects of osmolality on luminal fluid volume and drug absorption in rat intestine (jejunum, ileum and colon) were examined by means of an in situ closed loop method using fluorescein isothiocyanate-dextran 4000 (FD-4) and atenolol. In vivo absorption in rats was determined by measuring the plasma concentration after oral administration of the test compounds dissolved in purified water or hyperosmotic solution (10% NaCl).
RESULTS RESULTS
Administration of hyperosmotic solution directly into the GI tract significantly increased the GI fluid volume, owing to secretion of water into the lumen. After administration in hyperosmotic solution, the luminal concentration of non-permeable FD-4 was significantly lower than the initial dosing concentration, whereas after administration in purified water, the luminal concentration exceeded the initial concentration. The fraction absorbed of atenolol was markedly lower after administration in hyperosmotic solution than after administration in purified water. An in vivo pharmacokinetic study in rats was consistent with these findings.
CONCLUSIONS CONCLUSIONS
Administration of hyperosmotic NaCl solution increased GI fluid volume and reduced the plasma level of orally administered atenolol. This may imply that oral salt tablets used to treat hyponatremia in SIADH patients could decrease the intestinal absorption of concomitantly administered drugs, resulting in lower plasma exposure.

Identifiants

pubmed: 34465382
doi: 10.1186/s40780-021-00212-z
pii: 10.1186/s40780-021-00212-z
pmc: PMC8408929
doi:

Types de publication

Journal Article

Langues

eng

Pagination

29

Subventions

Organisme : Japan Society for the Promotion of Science
ID : 20K07165

Informations de copyright

© 2021. The Author(s).

Références

Am J Physiol. 1996 Jan;270(1 Pt 1):G29-41
pubmed: 8772498
Front Physiol. 2019 Oct 29;10:1334
pubmed: 31736772
Annu Rev Physiol. 2011;73:261-81
pubmed: 21054167
J Pharmacokinet Biopharm. 1978 Dec;6(6):547-58
pubmed: 731417
Mol Pharm. 2013 Jun 3;10(6):2261-9
pubmed: 23600944
Yakugaku Zasshi. 2020;140(5):599-608
pubmed: 32378658
J Pharm Sci. 2017 Sep;106(9):2889-2894
pubmed: 28450238
Pharm Res. 2009 Mar;26(3):560-7
pubmed: 19002566
Drug Metab Dispos. 2019 Apr;47(4):386-391
pubmed: 30622163
Pharm Res. 2010 Oct;27(10):2141-9
pubmed: 20686826
Acta Neurol Scand. 2018 Jul;138(1):4-11
pubmed: 29654708
J Endocrinol Invest. 2016 Sep;39(9):991-1001
pubmed: 27094044
J Pharm Sci. 2011 Sep;100(9):3843-53
pubmed: 21520088
Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G358-67
pubmed: 20466943
J Clin Invest. 1994 Jan;93(1):106-13
pubmed: 8282777
Nephrol Dial Transplant. 2014 Apr;29 Suppl 2:i1-i39
pubmed: 24569496
Mol Pharm. 2014 Sep 2;11(9):3039-47
pubmed: 25115349
J Pharm Pharmacol. 1997 Jul;49(7):687-90
pubmed: 9255712

Auteurs

Miyuki Takemura (M)

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.
School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.

Yuki Tanaka (Y)

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.

Katsuhisa Inoue (K)

School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.

Ikumi Tamai (I)

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan.

Yoshiyuki Shirasaka (Y)

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192, Japan. shira@p.kanazawa-u.ac.jp.
School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan. shira@p.kanazawa-u.ac.jp.

Classifications MeSH